SrasV1, PascalFrancis, Corpus, bibRecord, 000425

An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins : Structures, functions and drug development : SARS-CoV: A scénario of modern drug design

Identifieur interne : 000425 ( PascalFrancis/Corpus ); précédent : 000424; suivant : 000426

An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins : Structures, functions and drug development : SARS-CoV: A scénario of modern drug design

Auteurs : SHUAI CHEN ; HAIBIN LUO ; LILI CHEN ; JING CHEN ; JIANHUA SHEN ; WEILIANG ZHU ; KAIXIAN CHEN ; XU SHEN ; HUALIANG JIANG

Source :

Current pharmaceutical design [ 1381-6128 ] ; 2006.

RBID : Pascal:07-0053590

Descripteurs français

Pascal (Inist)
- Coronavirus, Syndrome respiratoire aigu sévère, Génome, Protéine, Fonction structure, Recherche développement, Médicament, Atypique, Pneumonie, Structure moléculaire, Inhibiteur, Criblage, Article synthèse.

English descriptors

KwdEn :
- Atypical, Coronavirus, Drug, Genome, Inhibitor, Molecular structure, Pneumonia, Protein, Research and development, Review, Screening, Severe acute respiratory syndrome, Structure function.

Abstract

A severe atypical pneumonia designated as severe acute respiratory syndrome (SARS) by The World Health Organization broke out in China and menaced to more than other 30 countries between the end of the year 2002 and June of the year 2003. A novel coronavirus called severe acute respiratory syndrome coronavirus (SARS-CoV) has been recently identified as the etiological agent responsible for the infectious SARS disease. Based on extensively scientific cooperation and almost two-year's studies, remarkable achievements have been made in the understanding of the phylogenetic property and the genome organization of SARS-CoV, as well as the detailed characters of the major proteins involved in SARS-CoV life cycle. In this review, we would like to summarize the substantial scientific progress that has been made towards the structural and functional aspects of SARS-CoV associated key proteins. The progress focused on the corresponding key proteins' structure-based drug and vaccine developments has been also highlighted. The concerted and cooperative response for the treatment of the SARS disease has been proved to be a triumph of global public health and provides a new paradigm for the detection and control of future emerging infectious disease threats.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1381-6128`
A03		`1`		`@0 Curr. pharm. des.`
A05				`@2 12`
A06				`@2 35`
A08	`01`	`1`	`ENG`	`@1 An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins : Structures, functions and drug development : SARS-CoV: A scénario of modern drug design`
A11	`01`	`1`		`@1 SHUAI CHEN`
A11	`02`	`1`		`@1 HAIBIN LUO`
A11	`03`	`1`		`@1 LILI CHEN`
A11	`04`	`1`		`@1 JING CHEN`
A11	`05`	`1`		`@1 JIANHUA SHEN`
A11	`06`	`1`		`@1 WEILIANG ZHU`
A11	`07`	`1`		`@1 KAIXIAN CHEN`
A11	`08`	`1`		`@1 XU SHEN`
A11	`09`	`1`		`@1 HUALIANG JIANG`
A14	`01`			`@1 Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences @2 Shanghai 201 203 @3 CHN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut. @Z 9 aut.`
A14	`02`			`@1 School of Pharmacy, East China University of Science and Technology @2 Shanghai 200237 @3 CHN @Z 8 aut. @Z 9 aut.`
A20				`@1 4539-4553`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 26320 @5 354000145201350010`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 106 ref.`
A47	`01`	`1`		`@0 07-0053590`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Current pharmaceutical design`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 A severe atypical pneumonia designated as severe acute respiratory syndrome (SARS) by The World Health Organization broke out in China and menaced to more than other 30 countries between the end of the year 2002 and June of the year 2003. A novel coronavirus called severe acute respiratory syndrome coronavirus (SARS-CoV) has been recently identified as the etiological agent responsible for the infectious SARS disease. Based on extensively scientific cooperation and almost two-year's studies, remarkable achievements have been made in the understanding of the phylogenetic property and the genome organization of SARS-CoV, as well as the detailed characters of the major proteins involved in SARS-CoV life cycle. In this review, we would like to summarize the substantial scientific progress that has been made towards the structural and functional aspects of SARS-CoV associated key proteins. The progress focused on the corresponding key proteins' structure-based drug and vaccine developments has been also highlighted. The concerted and cooperative response for the treatment of the SARS disease has been proved to be a triumph of global public health and provides a new paradigm for the detection and control of future emerging infectious disease threats.
C02	`01`	`X`		`@0 002B05C02C`
C02	`02`	`X`		`@0 002B02S05`
C03	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Génome @5 03`
C03	`03`	`X`	`ENG`	`@0 Genome @5 03`
C03	`03`	`X`	`SPA`	`@0 Genoma @5 03`
C03	`04`	`X`	`FRE`	`@0 Protéine @5 04`
C03	`04`	`X`	`ENG`	`@0 Protein @5 04`
C03	`04`	`X`	`SPA`	`@0 Proteína @5 04`
C03	`05`	`X`	`FRE`	`@0 Fonction structure @5 05`
C03	`05`	`X`	`ENG`	`@0 Structure function @5 05`
C03	`05`	`X`	`SPA`	`@0 Función estructura @5 05`
C03	`06`	`X`	`FRE`	`@0 Recherche développement @5 06`
C03	`06`	`X`	`ENG`	`@0 Research and development @5 06`
C03	`06`	`X`	`SPA`	`@0 Investigación desarrollo @5 06`
C03	`07`	`X`	`FRE`	`@0 Médicament @5 07`
C03	`07`	`X`	`ENG`	`@0 Drug @5 07`
C03	`07`	`X`	`SPA`	`@0 Medicamento @5 07`
C03	`08`	`X`	`FRE`	`@0 Atypique @5 08`
C03	`08`	`X`	`ENG`	`@0 Atypical @5 08`
C03	`08`	`X`	`SPA`	`@0 Atípico @5 08`
C03	`09`	`X`	`FRE`	`@0 Pneumonie @5 09`
C03	`09`	`X`	`ENG`	`@0 Pneumonia @5 09`
C03	`09`	`X`	`SPA`	`@0 Neumonía @5 09`
C03	`10`	`X`	`FRE`	`@0 Structure moléculaire @5 10`
C03	`10`	`X`	`ENG`	`@0 Molecular structure @5 10`
C03	`10`	`X`	`SPA`	`@0 Estructura molecular @5 10`
C03	`11`	`X`	`FRE`	`@0 Inhibiteur @5 12`
C03	`11`	`X`	`ENG`	`@0 Inhibitor @5 12`
C03	`11`	`X`	`SPA`	`@0 Inhibidor @5 12`
C03	`12`	`X`	`FRE`	`@0 Criblage @5 13`
C03	`12`	`X`	`ENG`	`@0 Screening @5 13`
C03	`12`	`X`	`SPA`	`@0 Cernido @5 13`
C03	`13`	`X`	`FRE`	`@0 Article synthèse @5 16`
C03	`13`	`X`	`ENG`	`@0 Review @5 16`
C03	`13`	`X`	`SPA`	`@0 Artículo síntesis @5 16`
C07	`01`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virose`
C07	`04`	`X`	`ENG`	`@0 Viral disease`
C07	`04`	`X`	`SPA`	`@0 Virosis`
C07	`05`	`X`	`FRE`	`@0 Infection`
C07	`05`	`X`	`ENG`	`@0 Infection`
C07	`05`	`X`	`SPA`	`@0 Infección`
C07	`06`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 37`
C07	`06`	`X`	`ENG`	`@0 Respiratory disease @5 37`
C07	`06`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 37`
C07	`07`	`X`	`FRE`	`@0 Poumon pathologie @5 38`
C07	`07`	`X`	`ENG`	`@0 Lung disease @5 38`
C07	`07`	`X`	`SPA`	`@0 Pulmón patología @5 38`
N21				`@1 036`

Format Inist (serveur)

NO :	PASCAL 07-0053590 INIST
ET :	An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins : Structures, functions and drug development : SARS-CoV: A scénario of modern drug design
AU :	SHUAI CHEN; HAIBIN LUO; LILI CHEN; JING CHEN; JIANHUA SHEN; WEILIANG ZHU; KAIXIAN CHEN; XU SHEN; HUALIANG JIANG
AF :	Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences/Shanghai 201 203/Chine (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut., 9 aut.); School of Pharmacy, East China University of Science and Technology/Shanghai 200237/Chine (8 aut., 9 aut.)
DT :	Publication en série; Niveau analytique
SO :	Current pharmaceutical design; ISSN 1381-6128; Pays-Bas; Da. 2006; Vol. 12; No. 35; Pp. 4539-4553; Bibl. 106 ref.
LA :	Anglais
EA :	A severe atypical pneumonia designated as severe acute respiratory syndrome (SARS) by The World Health Organization broke out in China and menaced to more than other 30 countries between the end of the year 2002 and June of the year 2003. A novel coronavirus called severe acute respiratory syndrome coronavirus (SARS-CoV) has been recently identified as the etiological agent responsible for the infectious SARS disease. Based on extensively scientific cooperation and almost two-year's studies, remarkable achievements have been made in the understanding of the phylogenetic property and the genome organization of SARS-CoV, as well as the detailed characters of the major proteins involved in SARS-CoV life cycle. In this review, we would like to summarize the substantial scientific progress that has been made towards the structural and functional aspects of SARS-CoV associated key proteins. The progress focused on the corresponding key proteins' structure-based drug and vaccine developments has been also highlighted. The concerted and cooperative response for the treatment of the SARS disease has been proved to be a triumph of global public health and provides a new paradigm for the detection and control of future emerging infectious disease threats.
CC :	002B05C02C; 002B02S05
FD :	Coronavirus; Syndrome respiratoire aigu sévère; Génome; Protéine; Fonction structure; Recherche développement; Médicament; Atypique; Pneumonie; Structure moléculaire; Inhibiteur; Criblage; Article synthèse
FG :	Coronaviridae; Nidovirales; Virus; Virose; Infection; Appareil respiratoire pathologie; Poumon pathologie
ED :	Coronavirus; Severe acute respiratory syndrome; Genome; Protein; Structure function; Research and development; Drug; Atypical; Pneumonia; Molecular structure; Inhibitor; Screening; Review
EG :	Coronaviridae; Nidovirales; Virus; Viral disease; Infection; Respiratory disease; Lung disease
SD :	Coronavirus; Síndrome respiratorio agudo severo; Genoma; Proteína; Función estructura; Investigación desarrollo; Medicamento; Atípico; Neumonía; Estructura molecular; Inhibidor; Cernido; Artículo síntesis
LO :	INIST-26320.354000145201350010
ID :	07-0053590

Links to Exploration step

Pascal:07-0053590

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins : Structures, functions and drug development : SARS-CoV: A scénario of modern drug design</title>
<author><name sortKey="Shuai Chen" sort="Shuai Chen" uniqKey="Shuai Chen" last="Shuai Chen">SHUAI CHEN</name>
<affiliation><inist:fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Haibin Luo" sort="Haibin Luo" uniqKey="Haibin Luo" last="Haibin Luo">HAIBIN LUO</name>
<affiliation><inist:fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lili Chen" sort="Lili Chen" uniqKey="Lili Chen" last="Lili Chen">LILI CHEN</name>
<affiliation><inist:fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jing Chen" sort="Jing Chen" uniqKey="Jing Chen" last="Jing Chen">JING CHEN</name>
<affiliation><inist:fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jianhua Shen" sort="Jianhua Shen" uniqKey="Jianhua Shen" last="Jianhua Shen">JIANHUA SHEN</name>
<affiliation><inist:fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weiliang Zhu" sort="Weiliang Zhu" uniqKey="Weiliang Zhu" last="Weiliang Zhu">WEILIANG ZHU</name>
<affiliation><inist:fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kaixian Chen" sort="Kaixian Chen" uniqKey="Kaixian Chen" last="Kaixian Chen">KAIXIAN CHEN</name>
<affiliation><inist:fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Xu Shen" sort="Xu Shen" uniqKey="Xu Shen" last="Xu Shen">XU SHEN</name>
<affiliation><inist:fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>School of Pharmacy, East China University of Science and Technology</s1>
<s2>Shanghai 200237</s2>
<s3>CHN</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hualiang Jiang" sort="Hualiang Jiang" uniqKey="Hualiang Jiang" last="Hualiang Jiang">HUALIANG JIANG</name>
<affiliation><inist:fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>School of Pharmacy, East China University of Science and Technology</s1>
<s2>Shanghai 200237</s2>
<s3>CHN</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0053590</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 07-0053590 INIST</idno>
<idno type="RBID">Pascal:07-0053590</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000425</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins : Structures, functions and drug development : SARS-CoV: A scénario of modern drug design</title>
<author><name sortKey="Shuai Chen" sort="Shuai Chen" uniqKey="Shuai Chen" last="Shuai Chen">SHUAI CHEN</name>
<affiliation><inist:fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Haibin Luo" sort="Haibin Luo" uniqKey="Haibin Luo" last="Haibin Luo">HAIBIN LUO</name>
<affiliation><inist:fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lili Chen" sort="Lili Chen" uniqKey="Lili Chen" last="Lili Chen">LILI CHEN</name>
<affiliation><inist:fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jing Chen" sort="Jing Chen" uniqKey="Jing Chen" last="Jing Chen">JING CHEN</name>
<affiliation><inist:fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jianhua Shen" sort="Jianhua Shen" uniqKey="Jianhua Shen" last="Jianhua Shen">JIANHUA SHEN</name>
<affiliation><inist:fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weiliang Zhu" sort="Weiliang Zhu" uniqKey="Weiliang Zhu" last="Weiliang Zhu">WEILIANG ZHU</name>
<affiliation><inist:fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kaixian Chen" sort="Kaixian Chen" uniqKey="Kaixian Chen" last="Kaixian Chen">KAIXIAN CHEN</name>
<affiliation><inist:fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Xu Shen" sort="Xu Shen" uniqKey="Xu Shen" last="Xu Shen">XU SHEN</name>
<affiliation><inist:fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>School of Pharmacy, East China University of Science and Technology</s1>
<s2>Shanghai 200237</s2>
<s3>CHN</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hualiang Jiang" sort="Hualiang Jiang" uniqKey="Hualiang Jiang" last="Hualiang Jiang">HUALIANG JIANG</name>
<affiliation><inist:fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>School of Pharmacy, East China University of Science and Technology</s1>
<s2>Shanghai 200237</s2>
<s3>CHN</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Current pharmaceutical design</title>
<title level="j" type="abbreviated">Curr. pharm. des.</title>
<idno type="ISSN">1381-6128</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Current pharmaceutical design</title>
<title level="j" type="abbreviated">Curr. pharm. des.</title>
<idno type="ISSN">1381-6128</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Atypical</term>
<term>Coronavirus</term>
<term>Drug</term>
<term>Genome</term>
<term>Inhibitor</term>
<term>Molecular structure</term>
<term>Pneumonia</term>
<term>Protein</term>
<term>Research and development</term>
<term>Review</term>
<term>Screening</term>
<term>Severe acute respiratory syndrome</term>
<term>Structure function</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Coronavirus</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Génome</term>
<term>Protéine</term>
<term>Fonction structure</term>
<term>Recherche développement</term>
<term>Médicament</term>
<term>Atypique</term>
<term>Pneumonie</term>
<term>Structure moléculaire</term>
<term>Inhibiteur</term>
<term>Criblage</term>
<term>Article synthèse</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A severe atypical pneumonia designated as severe acute respiratory syndrome (SARS) by The World Health Organization broke out in China and menaced to more than other 30 countries between the end of the year 2002 and June of the year 2003. A novel coronavirus called severe acute respiratory syndrome coronavirus (SARS-CoV) has been recently identified as the etiological agent responsible for the infectious SARS disease. Based on extensively scientific cooperation and almost two-year's studies, remarkable achievements have been made in the understanding of the phylogenetic property and the genome organization of SARS-CoV, as well as the detailed characters of the major proteins involved in SARS-CoV life cycle. In this review, we would like to summarize the substantial scientific progress that has been made towards the structural and functional aspects of SARS-CoV associated key proteins. The progress focused on the corresponding key proteins' structure-based drug and vaccine developments has been also highlighted. The concerted and cooperative response for the treatment of the SARS disease has been proved to be a triumph of global public health and provides a new paradigm for the detection and control of future emerging infectious disease threats.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1381-6128</s0>
</fA01>
<fA03 i2="1"><s0>Curr. pharm. des.</s0>
</fA03>
<fA05><s2>12</s2>
</fA05>
<fA06><s2>35</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins : Structures, functions and drug development : SARS-CoV: A scénario of modern drug design</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SHUAI CHEN</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>HAIBIN LUO</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>LILI CHEN</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>JING CHEN</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>JIANHUA SHEN</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>WEILIANG ZHU</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>KAIXIAN CHEN</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>XU SHEN</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>HUALIANG JIANG</s1>
</fA11>
<fA14 i1="01"><s1>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences</s1>
<s2>Shanghai 201 203</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>School of Pharmacy, East China University of Science and Technology</s1>
<s2>Shanghai 200237</s2>
<s3>CHN</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>4539-4553</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>26320</s2>
<s5>354000145201350010</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>106 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0053590</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Current pharmaceutical design</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>A severe atypical pneumonia designated as severe acute respiratory syndrome (SARS) by The World Health Organization broke out in China and menaced to more than other 30 countries between the end of the year 2002 and June of the year 2003. A novel coronavirus called severe acute respiratory syndrome coronavirus (SARS-CoV) has been recently identified as the etiological agent responsible for the infectious SARS disease. Based on extensively scientific cooperation and almost two-year's studies, remarkable achievements have been made in the understanding of the phylogenetic property and the genome organization of SARS-CoV, as well as the detailed characters of the major proteins involved in SARS-CoV life cycle. In this review, we would like to summarize the substantial scientific progress that has been made towards the structural and functional aspects of SARS-CoV associated key proteins. The progress focused on the corresponding key proteins' structure-based drug and vaccine developments has been also highlighted. The concerted and cooperative response for the treatment of the SARS disease has been proved to be a triumph of global public health and provides a new paradigm for the detection and control of future emerging infectious disease threats.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Génome</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Genome</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Genoma</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Protéine</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Protein</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Proteína</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Fonction structure</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Structure function</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Función estructura</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Recherche développement</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Research and development</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Investigación desarrollo</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Médicament</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Drug</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Medicamento</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Atypique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Atypical</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Atípico</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Pneumonie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Pneumonia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Neumonía</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Structure moléculaire</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Molecular structure</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Estructura molecular</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Inhibiteur</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Inhibitor</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Inhibidor</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Criblage</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Screening</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Cernido</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>16</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Review</s0>
<s5>16</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>16</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>38</s5>
</fC07>
<fN21><s1>036</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 07-0053590 INIST</NO>
<ET>An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins : Structures, functions and drug development : SARS-CoV: A scénario of modern drug design</ET>
<AU>SHUAI CHEN; HAIBIN LUO; LILI CHEN; JING CHEN; JIANHUA SHEN; WEILIANG ZHU; KAIXIAN CHEN; XU SHEN; HUALIANG JIANG</AU>
<AF>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences/Shanghai 201 203/Chine (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut., 9 aut.); School of Pharmacy, East China University of Science and Technology/Shanghai 200237/Chine (8 aut., 9 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Current pharmaceutical design; ISSN 1381-6128; Pays-Bas; Da. 2006; Vol. 12; No. 35; Pp. 4539-4553; Bibl. 106 ref.</SO>
<LA>Anglais</LA>
<EA>A severe atypical pneumonia designated as severe acute respiratory syndrome (SARS) by The World Health Organization broke out in China and menaced to more than other 30 countries between the end of the year 2002 and June of the year 2003. A novel coronavirus called severe acute respiratory syndrome coronavirus (SARS-CoV) has been recently identified as the etiological agent responsible for the infectious SARS disease. Based on extensively scientific cooperation and almost two-year's studies, remarkable achievements have been made in the understanding of the phylogenetic property and the genome organization of SARS-CoV, as well as the detailed characters of the major proteins involved in SARS-CoV life cycle. In this review, we would like to summarize the substantial scientific progress that has been made towards the structural and functional aspects of SARS-CoV associated key proteins. The progress focused on the corresponding key proteins' structure-based drug and vaccine developments has been also highlighted. The concerted and cooperative response for the treatment of the SARS disease has been proved to be a triumph of global public health and provides a new paradigm for the detection and control of future emerging infectious disease threats.</EA>
<CC>002B05C02C; 002B02S05</CC>
<FD>Coronavirus; Syndrome respiratoire aigu sévère; Génome; Protéine; Fonction structure; Recherche développement; Médicament; Atypique; Pneumonie; Structure moléculaire; Inhibiteur; Criblage; Article synthèse</FD>
<FG>Coronaviridae; Nidovirales; Virus; Virose; Infection; Appareil respiratoire pathologie; Poumon pathologie</FG>
<ED>Coronavirus; Severe acute respiratory syndrome; Genome; Protein; Structure function; Research and development; Drug; Atypical; Pneumonia; Molecular structure; Inhibitor; Screening; Review</ED>
<EG>Coronaviridae; Nidovirales; Virus; Viral disease; Infection; Respiratory disease; Lung disease</EG>
<SD>Coronavirus; Síndrome respiratorio agudo severo; Genoma; Proteína; Función estructura; Investigación desarrollo; Medicamento; Atípico; Neumonía; Estructura molecular; Inhibidor; Cernido; Artículo síntesis</SD>
<LO>INIST-26320.354000145201350010</LO>
<ID>07-0053590</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000425 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000425 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:07-0053590
   |texte=   An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins : Structures, functions and drug development : SARS-CoV: A scénario of modern drug design
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins : Structures, functions and drug development : SARS-CoV: A scénario of modern drug design

An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins : Structures, functions and drug development : SARS-CoV: A scénario of modern drug design

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri